Cocrystal Pharma Inc Stock Price, News & Analysis

Cocrystal Pharma (NASDAQ: COCP) has announced its participation in the Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference. The company's management will engage in a fireside chat on Thursday, June 5, 2025, at 12:00 p.m. Eastern time.

The event will feature a live Q&A session, and qualified investors can request one-on-one meetings with management through the conference platform. A video webcast of the presentation will be available within 48 hours on both the Cocrystal website and Channelchek, where it will remain accessible for 90 days.

Cocrystal Pharma (NASDAQ: COCP) announces significant progress with its norovirus oral antiviral candidate CDI-988, which has demonstrated potent activity against emerging GII.17 variants that have become the dominant strain in 2024-2025 U.S. and European outbreaks. The drug candidate shows broad-spectrum antiviral activity against both GII.4 and GII.17 strains.

CDI-988, a pan-viral protease inhibitor, has completed Phase 1 trials with favorable safety and tolerability results. The company plans to initiate a human challenge study in 2025 for both treatment and prevention of norovirus infection. The drug targets the highly conserved region of the GII.17 protease, representing a potential first-in-class oral antiviral treatment.

Notably, norovirus causes approximately 685 million cases and 50,000 child deaths annually worldwide, with an estimated societal cost of $60 billion. Currently, there are no approved antiviral treatments or vaccines available.

Cocrystal Pharma (Nasdaq: COCP) has announced its participation in the upcoming Life Science Innovation Northwest (LSINW) 2025 Conference. Sam Lee, President and co-CEO, will deliver a company overview presentation on Wednesday, April 23, 2025 at 3:00 p.m. Pacific time. The conference will take place at the Seattle Convention Center from April 23-24.

Cocrystal Pharma (COCP) reported financial results for 2024 and provided updates on its antiviral drug development programs. The company reported a net loss of $17.5 million ($1.72 per share) compared to $18.0 million in 2023. R&D expenses decreased to $12.5 million from $15.2 million, while G&A expenses reduced to $5.3 million from $6.0 million.

The company's cash position stood at $9.9 million as of December 31, 2024, down from $26.4 million year-over-year. Key developments include plans to initiate a norovirus human challenge study for CDI-988 and continuation of the influenza challenge study for CC-42344. The company's pipeline focuses on developing treatments for norovirus, influenza, and coronavirus using their proprietary structure-based drug discovery platform.

Cocrystal Pharma (Nasdaq: COCP) has announced its participation in the Zacks SCR Life Sciences Virtual Investor Forum scheduled for March 13, 2025. The company's management will engage in a fireside chat at 11:30 a.m. Eastern time (8:30 a.m. Pacific time), hosted by Zacks Small Cap Research Senior Analyst David Bautz, PhD.

Investors can pre-register for the virtual presentation through Cocrystal's website and will have the opportunity to:

• Submit questions during the live event
• Request one-on-one meetings with management via the 'Book A Meeting' button
• Access a replay of the event through the company's website

Cocrystal Pharma (NASDAQ: COCP) has reported positive Phase 1 results for CDI-988, its oral protease inhibitor designed as a pan-viral treatment for norovirus and coronavirus infections. The multiple-ascending dose (MAD) study demonstrated favorable safety and tolerability at dosing up to 800 mg daily for 10 consecutive days.

The company plans to conduct an additional cohort study with a higher dose of 1,200 mg for five consecutive days to further evaluate safety, tolerability, and pharmacokinetics. CDI-988, developed using Cocrystal's proprietary structure-based drug discovery platform, has shown pan-viral activity against multiple norovirus strains, particularly the GII.4 viruses.

With nearly 900 cruise ship passengers affected by gastrointestinal disease in December alone and no currently approved antivirals or vaccines for norovirus, Cocrystal aims to initiate a human challenge study in norovirus-infected subjects later in 2025.

Cocrystal Pharma (NASDAQ: COCP) announces plans to extend enrollment in their Phase 2a human challenge study for CC-42344, their oral influenza PB2 inhibitor, due to unexpectedly low influenza infection rates among study participants. While the drug demonstrated a favorable safety and tolerability profile with no serious adverse events or drug-related discontinuations, the low infectivity of the H3N2 viral strain used in the study made virology results uninterpretable.

The company is working with their clinical research organization to prepare a protocol amendment for UK MHRA approval to extend enrollment and ensure necessary infection rates. CC-42344 is being developed as an oral treatment for pandemic avian and seasonal influenza A infections, featuring a unique mechanism of action with a high barrier to developing resistance.